Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEANEX: Exemestane Switch After Anastrozole/Letrozole in HR+ Breast Cancer
NCT00902954Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Mar 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane in breast cancer, sponsored by Fudan University. Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00902954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902954.